RNS Number:4552N
Celsis International PLC
07 February 2008



                         CELSIS INTERNATIONAL PLC
                ("Celsis", "the Company" or "the Group")

                      INTERIM MANAGEMENT STATEMENT

7 February 2008: Celsis International plc, the life sciences products and
laboratory services company, today provides its Interim Management Statement for
the quarter ended 31 December 2007.

Celsis has continued to see strong trading into the second half of the financial
year following its positive interim results.  Excellent performances have been
seen from the Rapid Detection and In Vitro Technologies divisions, particularly
during December, and the Group overall continues to trade in line with the
Board's expectations.

The Rapid Detection division, which provides rapid microbial detection systems
to more quickly ensure product safety and quality, has continued to build on its
solid first half instrument placements and reagent and consumable sales, with
strong demand across all geographical regions and sectors of this business.
This positive trend is expected to continue for the remainder of the financial
year.

The In Vitro Technologies division, which provides in vitro products and
development services to the pharmaceutical and biotechnology industries to
reduce the time and cost of drug discovery and development, remains on track and
has seen very good trading during this quarter.  Encouraging growth from this
division is expected to continue as its sales team builds momentum and
strengthens its presence in both North America and the EU.  First full year
results from the IVT division are expected to be healthy with a strong mix of
product sales.

The Analytical Services division, which provides outsourced laboratory testing
services to the pharmaceutical industry, has seen good progress from three of
its four business areas in this quarter, although there has been continued
consolidation of the Celsis New Jersey chemistry business following excellent
prior year performance.  Focused marketing and business development plans are in
place to recover this segment but are not likely to come to full fruition before
the year end.  Although the other three businesses are progressing well, the
Analytical Services division is expected to complete the full year slightly down
on last year's exceptional 25% increase.

Commenting on today's announcement, Jay LeCoque, CEO of Celsis said:  "Celsis is
well positioned to grow organically, with progress in the Rapid Detection and In
Vitro Technologies divisions being particularly encouraging during the quarter.
In addition, we continue to review new acquisition opportunities.  Overall, the
Company looks forward to a positive year end performance, with revenue and
profit growth in line with the Board's expectations."

ENQUIRIES:

Celsis International plc                                      Tel: 01223 598 428
Jay LeCoque, Chief Executive Officer
Christian Madrolle, Finance Director and Company Secretary


Financial Dynamics                                            Tel: 020 7831 3113
Ben Atwell
David Yates

Notes to editors

Celsis International plc

Celsis International plc is a world leading provider of innovative life science
products and laboratory services to the pharmaceutical, biopharmaceutical, and
consumer products industries through its three business areas; rapid detection,
analytical and drug development services and ADME-Tox in vitro technologies.
The company is listed on the London Stock Exchange (CEL.L)

Each division of Celsis International plc has the capacity to deliver
substantial time and cost savings to its customers, in addition to ensuring
product quality and safety for consumers.  Celsis Rapid Detection division
utilises proprietary enzyme technology to develop and supply diagnostic testing
instruments and consumables for the rapid detection of microbial contamination
in pharmaceutical and consumer products.  These rapid testing systems provide
significant economic value by reducing the time it takes to test and release raw
materials, in process and finished goods to market.  Celsis Analytical Services
division provides cost effective outsourced laboratory testing services to
pharmaceutical and biopharmaceutical companies.  Its comprehensive service
offerings include a full spectrum of laboratory services from drug development
and discovery to analytical chemistry and biological sciences to stability
storage and testing.  Celsis In Vitro Technologies (Celsis IVT) employs
proprietary expertise in hepatocyte (liver cell) technology to supply in vitro
testing products to the pharmaceutical and biotechnology industries.  Celsis
IVT's consumable testing products screen drug compounds for liver toxicity early
in the drug discovery process, thereby reducing the time and cost of further
development or trial on those compounds which will not be properly metabolised
by the human liver.

Further information can be found on its website at www.celsis.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

IMSUUUBUPUPRGQQ
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.